SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the ...
Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc ...
South Korea: In a post hoc analysis of the randomized PULSAR trial, aflibercept 8 mg demonstrated noninferior visual outcomes ...
At the European Society of Cardiology (ESC) Congress 2025, findings from a post-hoc analysis of the SURMOUNT-5 trial (NCT05822830) were presented, comparing tirzepatide to semaglutide for their impact ...
Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker ...
This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...
In a post-hoc analysis of the ADVANCE and MOTIVATE phase III induction studies, along with the FORTIFY maintenance study, researchers evaluated the safety profile of risankizumab (Skyrizi) in patients ...
MedPage Today on MSN
Higher-Dose Aflibercept Similar to Standard Dose in Severe AMD Variant
In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback